Evidence map›Paper›PMID 21647677›Full record

ArticleBreast cancer research and treatment2012

Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways.

Catherine Ibarra-Drendall, Michelle M Troch, William T Barry, Gloria Broadwater, Emanuel F Petricoin, Julia Wulfkuhle, Lance A Liotta, Siya Lem, Joseph C Baker, Anne C Ford and 12 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Tumor mechanics and metabolic dysfunction.Free radical biology & medicine · 2015
    Review
  6. Review
  7. Article
  8. Review
  9. Random periareolar fine-needle aspiration: the new pap smear of the breast?Journal of the advanced practitioner in oncology · 2012
    Review
  10. Article
  11. -Omics and cancer biomarkers: link to the biological truth or bear the consequences.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2012
    Article
  12. Lactation and neonatal nutrition: defining and refining the critical questions.Journal of mammary gland biology and neoplasia · 2012
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

22 authors at 5 institutions in 1 country.

Catherine Ibarra-DrendallDivision of Medical Oncology, Duke University Medical Center, Box 2628, Durham, NC 27710, USA. ibarr001@mc.duke.edu
Michelle M Troch
William T Barry
Gloria Broadwater
Emanuel F Petricoin
Julia Wulfkuhle
Lance A Liotta
Siya Lem
Joseph C Baker
Anne C Ford
Lee G Wilke
Carola Zalles
Nicole M Kuderer
Abigail W Hoffman
Melanie Shivraj
Priya Mehta
Jamila Williams
Nora Tolbert
Laurie W Lee
Patrick G Pilie
Dihua Yu
Victoria L Seewaldt
Duke Medical Center · USGeorge Mason University · USTexas A&M Health Science Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Wisconsin–Madison · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
Extracellular Matrix Mediated Apoptosis in p53 (-) HMECsR01CA088799 · NCI · DUKE UNIVERSITY · PI SEEWALDT, VICTORIA L. · 2001 to 2010
$2.7M
KCNK9 Imprinting in Breast Cancer Progression and MetastasisR01CA155664 · NCI · DUKE UNIVERSITY · PI SEEWALDT, VICTORIA L. · 2011 to 2015
$1.8M
Targeted Chemoprevention of Breast Cancer: From the Bench to Clinical TestingR01CA158668 · NCI · DUKE UNIVERSITY · PI SEEWALDT, VICTORIA L. · 2012 to 2016
$1.7M
p53 loss in HMECs: a model of breast cancer preventionR01CA098441 · NCI · DUKE UNIVERSITY · PI SEEWALDT, VICTORIA L. · 2003 to 2007
$1.5M
Molecular markers of breast cancer risk and preventionR01CA114068 · NCI · DUKE UNIVERSITY · PI SEEWALDT, VICTORIA L. · 2006 to 2010
$1.3M
NCI NIH HHS 3 P30 CA014236-32S1NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA088799NCI NIH HHS R01 CA098441NCI NIH HHS R01 CA114068NCI NIH HHS R01CA114068NCI NIH HHS R01 CA155664NCI NIH HHS R01 CA158668NCI NIH HHS R01CA88799
6 · The paper itself

Abstract

Normal mammary gland homeostasis requires the coordinated regulation of protein signaling networks. However, we have little prospective information on whether activation of protein signaling occurs in premalignant mammary epithelial cells, as represented by cells with cytological atypia from women who are at high risk for breast cancer. This information is critical for understanding the role of deregulated signaling pathways in the initiation of breast cancer and for developing targeted prevention and/or treatment strategies for breast cancer in the future. In this pilot and feasibility study, we examined the expression of 52 phosphorylated, total, and cleaved proteins in 31 microdissected Random Periareolar Fine Needle Aspiration (RPFNA) samples by high-throughput Reverse Phase Protein Microarray. Unsupervised hierarchical clustering analysis indicated the presence of four clusters of proteins that represent the following signaling pathways: (1) receptor tyrosine kinase/Akt/mammalian target of rapamycin (RTK/Akt/mTOR), (2) RTK/Akt/extracellular signal-regulated kinase (RTK/Akt/ERK), (3) mitochondrial apoptosis, and (4) indeterminate. Clusters 1 through 3 comprised moderately to highly expressed proteins, while Cluster 4 comprised proteins that are lowly expressed in a majority of RPFNA samples. Our exploratory study showed that the interlinked components of mitochondrial apoptosis pathway are highly expressed in all mammary epithelial cells obtained from high-risk women. In particular, the expression levels of anti-apoptotic Bcl-xL and pro-apoptotic Bad are positively correlated in both non-atypical and atypical samples (unadjusted P < 0.0001), suggesting a delicate balance between the pro-apoptotic and anti-apoptotic regulation of cell proliferation during the early steps of mammary carcinogenesis. Our feasibility study suggests that the activation of key proteins along the RTK/Akt pathway may tip this balance to cell survival. Taken together, our results demonstrate the feasibility of mapping proteomic signaling networks in limited RPFNA samples obtained from high-risk women and the promise of developing rational drug targets or preventative strategies for breast cancer in future proteomic studies with a larger cohort of high-risk women.

Indexed as

ProteomicsSignal TransductionAdultAgedApoptosisApoptosis Regulatory ProteinsBiopsy, Fine-NeedleBreast NeoplasmsCell Cycle ProteinsCell SurvivalCluster AnalysisFeasibility StudiesFemaleHigh-Throughput Screening AssaysHumansLogistic ModelsApoptosis Regulatory ProteinsCell Cycle Proteins

Identifiers

PMID21647677
PMCPMC3638770
OpenAlexW2082934714

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.